Transcode Therapeutics, Inc. (RNAZ): Nasdaq/NYSE listing notice — TransCode Therapeutics faces Nasdaq delisting after compliance plan rejected; hearing set for Oct 2023

Transcode Therapeutics, Inc.

Nasdaq rejected compliance plan on July 26, 2023, for failing to meet $2.5M stockholders' equity requirement.
Company appealed; oral hearing before Nasdaq Hearings Panel scheduled for October 2023.
Delisting action stayed until hearing held and final written decision issued.
No assurance that plan will be accepted or that compliance can be regained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Transcode Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5815(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5815(a)(2)

Exact text from the filing

that the Staff had determined not to accept the Company’s Compliance Plan, that the Company’s request for an extension had been denied, and that the Company’s common stock was subject to delisting from the Nasdaq Capital Market (the “Delisting Determination”). In accordance with Nasdaq Listing Rule 5815(a)(2), the Company was provided with seven calendar days, or until August 2, 2023, to request a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Delisting Determination. The Company subsequently submitted a request for a hearing to Nasdaq, and on August 2, 2023, was notified

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-087574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.